Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 68.9 Cr.
- Current Price ₹ 35.5
- High / Low ₹ 43.8 / 28.0
- Stock P/E 62.0
- Book Value ₹ 23.8
- Dividend Yield 0.00 %
- ROCE 8.49 %
- ROE 3.68 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -24.6% over past five years.
- Promoter holding is low: 5.98%
- Company has a low return on equity of -22.7% over last 3 years.
- Promoter holding has decreased over last 3 years: -32.7%
- Working capital days have increased from 26.7 days to 89.0 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 0.00 | 243.48 | 191.10 | 212.29 | 150.59 | 75.00 | 59.40 | |
| 0.01 | 235.33 | 177.94 | 204.63 | 143.39 | 91.28 | 50.91 | |
| Operating Profit | -0.01 | 8.15 | 13.16 | 7.66 | 7.20 | -16.28 | 8.49 |
| OPM % | 3.35% | 6.89% | 3.61% | 4.78% | -21.71% | 14.29% | |
| 0.00 | 0.39 | 0.29 | 0.12 | 0.46 | 1.99 | 0.10 | |
| Interest | 0.00 | 2.67 | 2.09 | 3.38 | 4.78 | 3.98 | 4.89 |
| Depreciation | 0.00 | 1.81 | 2.02 | 2.37 | 2.52 | 2.50 | 2.41 |
| Profit before tax | -0.01 | 4.06 | 9.34 | 2.03 | 0.36 | -20.77 | 1.29 |
| Tax % | 0.00% | 56.16% | 28.91% | 38.42% | -183.33% | -2.79% | 13.18% |
| -0.01 | 1.78 | 6.64 | 1.25 | 1.03 | -20.19 | 1.11 | |
| EPS in Rs | -0.11 | 0.93 | 3.46 | 0.65 | 0.54 | -10.52 | 0.58 |
| Dividend Payout % | 0.00% | 0.00% | 13.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -35% |
| TTM: | -21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -4% |
| TTM: | 105% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -11% |
| 3 Years: | -6% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -23% |
| Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 9.22 | 9.22 | 9.22 | 9.22 | 9.22 | 19.21 |
| Reserves | -0.01 | 17.40 | 24.00 | 24.46 | 25.51 | 5.43 | 26.40 |
| 0.00 | 12.48 | 26.51 | 31.09 | 44.30 | 40.05 | 45.33 | |
| 0.00 | 69.64 | 73.59 | 51.08 | 37.84 | 39.84 | 33.84 | |
| Total Liabilities | 0.40 | 108.74 | 133.32 | 115.85 | 116.87 | 94.54 | 124.78 |
| 0.00 | 19.67 | 21.38 | 26.65 | 26.92 | 25.46 | 24.24 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.12 | 0.14 | 0.13 | 0.18 | 0.21 | 0.19 |
| 0.40 | 88.95 | 111.80 | 89.07 | 89.77 | 68.87 | 100.35 | |
| Total Assets | 0.40 | 108.74 | 133.32 | 115.85 | 116.87 | 94.54 | 124.78 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 0.00 | 27.49 | 7.63 | -9.62 | -6.61 | 11.49 | -12.03 | |
| 0.00 | -7.81 | -3.68 | -6.69 | -2.22 | -3.18 | -1.11 | |
| 0.00 | 18.62 | 11.96 | 0.27 | 8.43 | -8.23 | 29.74 | |
| Net Cash Flow | 0.00 | 38.30 | 15.91 | -16.03 | -0.40 | 0.08 | 16.60 |
| Free Cash Flow | 0.00 | 27.49 | 7.63 | -17.25 | -9.40 | 10.44 | -13.23 |
| CFO/OP | 0% | 327% | 82% | -87% | -88% | -71% | -144% |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 64.03 | 69.14 | 60.45 | 76.59 | 64.48 | 70.05 | |
| Inventory Days | 73.12 | 109.19 | 97.79 | 158.26 | 259.67 | 606.03 | |
| Days Payable | 114.08 | 161.20 | 73.90 | 103.37 | 174.65 | 239.52 | |
| Cash Conversion Cycle | 23.07 | 17.13 | 84.34 | 131.48 | 149.50 | 436.56 | |
| Working Capital Days | 14.41 | -19.46 | 20.63 | 28.48 | -37.28 | 88.98 | |
| ROCE % | 34.08% | 23.13% | 8.69% | 6.65% | -27.95% | 8.49% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Export Revenue as % of Total Revenue % |
|
||||
| Permanent Employees on Roll count |
|||||
| Related Party Sales as % of Total Revenue % |
|||||
| Number of Production Batches count |
|||||
| Number of Products Manufactured count |
|||||
| Total Dispatched Volume kg |
|||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Grant Of Extension Of Time By The Registrar Of Companies For Holding The 10St Annual General Meeting Of The Company
- ROC Hyderabad grants two-month extension to hold Vineet Laboratories' 10th AGM by 30 November 2026.
-
Results-Delay in Financial Results
- Board approved FY26 audited results on August 25, 2026; typo corrected in approval date.
- Results-Delay in Financial Results
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, August 25, 2026 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
- Approved audited FY26 results; Q4 profit Rs72.51 lakh, annual profit Rs111.08 lakh, unmodified audit opinion.
-
Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015.
- Board meets on 25 August 2026 to approve audited standalone FY2026 results.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
Business Overview[1]
The Co. manufactures and distributes pharmaceuticals, bulk drugs, chemicals, and pesticides. The company also conducts R&D across the biotechnology, healthcare, and industrial sectors, specializing in the export and import of various chemical formulations.